Prognostic Significance of CA 125 and TPS Levels after 3 Chemotherapy Courses in Ovarian Cancer Patients

Dalen, A. van; Favier, Judith; Burges, Alexander; Hasholzner, U; Bruijn, H.W.A. de; Dobler-Girdziunaite, D.; Dombi, V.; Fink, Daniel; Giai, M; McGing, P.; Harłozińska, A; Kainz, Ch.; Markowska, Janina; Molina, Rafael; Sturgeon, C.; Bowman, A.; Einarsson, R.

doi:10.1006/gyno.2000.5982

Cited by 44 publications

(35 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preoperative sensitivity and specificity could be improved by combination with other cancer antigens, such as CA15-3 and CA72-4 (14,16). Further, prognostic value of CA125 values was found (18,19). In addition, CA125 mirrors the recurrence of disease in blood accurately and frequently with a lead time of several months prior to radiological detectable tumor manifestations (2,9,(20)(21)(22), Finally, the therapy efficacy can be monitored effectively by the course of CA125, if interpreted by experts (2,9,(20)(21)(22).…”

Section: Bereitgestellt Von | Universitaetsbibliothek Der Lmu Muenchenmentioning

confidence: 99%

Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System

Holdenrieder¹,

Molina²,

Gion³

et al. 2008

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

Background: Cancer antigen CA125 is known as a valuable marker for the management of ovarian cancer. Methods: The analytical and clinical performance of the Access OV Monitor Immunoassay System (Beckman Coulter) was evaluated at five different European sites and compared with a reference system, defined as CA125 on the Elecsys System (Roche Diagnostics). Results: Total imprecision (%CV) of the OV Monitor ranged between 3.1% and 8.8%, and inter-laboratory reproducibility between 4.7% and 5.0%. Linearity upon dilution showed a mean recovery of 100% (SDq8.1%). Endogenous interferents had no influence on OV Monitor levels (mean recoveries: hemoglobin 107%, bilirubin 103%, triglycerides 103%). There was no high-dose hook effect up to 27,193 kU/L. Clinical performance investigated in sera from 1811 individuals showed a good correlation between the Access OV Monitor and Elecsys CA125 (Rs0.982, slopes0.921, interceptsq1.951). OV Monitor serum levels were low in healthy individuals (ns267, medians9.7 kU/L, 95th percentiles30.8 kU/L), higher in individuals with various benign diseases (ns549, medianss10.9-16.4 kU/L, 95th percentiless44.2-355 kU/L) and even higher in individuals suffering from various cancers (ns995, medianss12.4-445

show abstract

Section: Bereitgestellt Von | Universitaetsbibliothek Der Lmu Muenchenmentioning

confidence: 99%

Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System

Holdenrieder¹,

Molina²,

Gion³

et al. 2008

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Lavin et al 16 reported that persistence of elevated serum CA-125 levels despite the 3rd chemotherapy administration, would show the poor responders. Dalen et al 17 also reported that patients who have high preoperative CA-125 levels and whose CA-125 levels did not return to normal levels after the 3rd cycle of chemotherapy, would have poor prognosis. The first clinical study in the literature about total plasma LPA and gynecologic malignancies was published by Xu et al, 3 in 1998.…”

Section: Discussionmentioning

confidence: 99%

Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer

Beşe¹,

Barbaros

Baykara

et al. 2010

J Gynecol Oncol

View full text Add to dashboard Cite

Objective:To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer. Methods: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study. Twenty-nine of 87 epithelial ovarian cancer patients were followed up for 6 cycles of paclitaxel-carboplatin chemotherapy. CA-125 and total plasma LPA levels were measured preoperatively and before each chemotherapy cycle. Results: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women. Cut-off value for LPA was determined as 1.3 μmol/L and sensitivity, specificity, positive predictive value and negative predictive value were 95%, 92%, 95% and 92%, respectively. Mean total plasma LPA level of 29 patients who received chemotherapy was 7.21±6.63 μmol/L preoperatively and 6.84±6.34 μmol/L, 6.34±5.92 μmol/L, 6.14±5.79 μmol/L, 5.86±5.68 μmol/L, 5.23±5.11 μmol/L and 5.21±5.32 μmol/L in measurements held just before the 1st, 2nd, 3rd, 4th, 5th and 6th chemotherapy cycles, respectively (ANOVA, p=0.832). Total plasma LPA levels decreased slightly with chemotherapy administration and there was a weak negative correlation (Spearman, rs=−0.151, p=0.034), compared to a significant negative correlation in CA-125 (Spearman, rs=−0.596, p＜0.001). Conclusion: LPA is a better biomarker for diagnosis of epithelial ovarian cancer compared to CA-125. However, measurement of total plasma LPA levels during chemotherapy administration have no superiority to the serum CA-125 levels.

show abstract

“…Also, TPS and CA125 levels could be used as good predictors of recurrence in ovarian cancer (16). TPS in combination with CA125 has improved the detection of recurrent ovarian cancer (8) and in combination they increase the prognostic accuracy after chemotherapy (18).…”

Section: Discussionmentioning

confidence: 99%

Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer

Upadhya

Vasudevan

2003

Indian J Clin Biochem

View full text Add to dashboard Cite

The study was designed to evaluate the significance of tissue polypeptide specific antigen (TPS) in patients with histologically proven ovarian and colorectal cancer following treatment along with CA125 (in ovarian cancer) and CEA (in colorectal cancer). Patients were grouped as follows :Group I: Patients with stable disease Group II: Patients with metastasis and relapseIn patients with ovarian and colorectal cancer, the mean TPS levels were significantly higher in patients of group II compared to group I. The percentage of patients above cut-off levels for TPS were 17.4% in group I and 95.5% in group II. Similar results were observed with the mean levels of CA125. In colorectal cancer patients, the percentage of patients above cut-off levels for CEA and TPS were 70% and 30% in group I and 100% in group II for both the markers. Our observations indicate that TPS may be used as a common marker to indicate metastases in patients with ovarian and colorectal cancer.

show abstract

Prognostic Significance of CA 125 and TPS Levels after 3 Chemotherapy Courses in Ovarian Cancer Patients

Cited by 44 publications

References 24 publications

Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System

Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System

Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer

Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer

Contact Info

Product

Resources

About